BACKGROUND: It is unclear whether the presence of kidney disease modifies the associations of uric acid with cardiovascular events and death. METHODS: In the limited access, public use Atherosclerosis Risk In Communities (ARIC) database, associations of serum uric acid levels with cardiovascular events and death were analysed using a parametric proportional hazards model and the modification of these associations by the presence of CKD was assessed using a likelihood ratio test. RESULTS: Of the 15 366 ARIC participants included in this analysis, 461 had CKD (eGFR <60 ml/min/1.73 m(2)). In both non-CKD and CKD sub-groups, participants with hyperuricaemia (> or = 7 mg/dl in men and > or = 6 mg/dl in women) compared to those with normal serum uric acid levels had higher waist circumference and fasting serum insulin levels. In the entire cohort, in a multivariate parametric proportional hazards model, each mg/dl increase in serum uric acid was associated with an increased hazard of cardiovascular events (HR 1.09, 95% CI 1.05-1.12) and death. A multiplicative interaction term of serum uric acid and CKD when added to the above models was significant (P < 0.001). The likelihood ratio test of the models with and without the interaction term was also significant (P < 0.001). In the non-CKD population, a multivariate analysis after adjusting for comorbidities and metabolic syndrome showed a significant association between hyperuricaemia and mortality (HR 1.18, 95% CI 1.04-1.33) but not for cardiovascular events (HR 1.07, 95% CI 0.96-1.19). In the CKD population, the association was not significant for both mortality and cardiovascular events. CONCLUSION: We conclude that hyperuricaemia is associated with insulin resistance and mortality in the non-CKD population. The presence of CKD attenuates the associations of uric acid with mortality. Interventional studies are warranted to establish the biological role of hyperuricaemia in mortality in non-CKD and CKD populations.
BACKGROUND: It is unclear whether the presence of kidney disease modifies the associations of uric acid with cardiovascular events and death. METHODS: In the limited access, public use Atherosclerosis Risk In Communities (ARIC) database, associations of serum uric acid levels with cardiovascular events and death were analysed using a parametric proportional hazards model and the modification of these associations by the presence of CKD was assessed using a likelihood ratio test. RESULTS: Of the 15 366 ARIC participants included in this analysis, 461 had CKD (eGFR <60 ml/min/1.73 m(2)). In both non-CKD and CKD sub-groups, participants with hyperuricaemia (> or = 7 mg/dl in men and > or = 6 mg/dl in women) compared to those with normal serum uric acid levels had higher waist circumference and fasting serum insulin levels. In the entire cohort, in a multivariate parametric proportional hazards model, each mg/dl increase in serum uric acid was associated with an increased hazard of cardiovascular events (HR 1.09, 95% CI 1.05-1.12) and death. A multiplicative interaction term of serum uric acid and CKD when added to the above models was significant (P < 0.001). The likelihood ratio test of the models with and without the interaction term was also significant (P < 0.001). In the non-CKD population, a multivariate analysis after adjusting for comorbidities and metabolic syndrome showed a significant association between hyperuricaemia and mortality (HR 1.18, 95% CI 1.04-1.33) but not for cardiovascular events (HR 1.07, 95% CI 0.96-1.19). In the CKD population, the association was not significant for both mortality and cardiovascular events. CONCLUSION: We conclude that hyperuricaemia is associated with insulin resistance and mortality in the non-CKD population. The presence of CKD attenuates the associations of uric acid with mortality. Interventional studies are warranted to establish the biological role of hyperuricaemia in mortality in non-CKD and CKD populations.
Authors: Christoph Bickel; Hans J Rupprecht; Stefan Blankenberg; Gerd Rippin; Gerd Hafner; Alexander Daunhauer; Klaus-Peter Hofmann; Jürgen Meyer Journal: Am J Cardiol Date: 2002-01-01 Impact factor: 2.778
Authors: Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak Journal: J Am Coll Cardiol Date: 2003-01-01 Impact factor: 24.094
Authors: Colin A J Farquharson; Robert Butler; Alexander Hill; Jill J F Belch; Allan D Struthers Journal: Circulation Date: 2002-07-09 Impact factor: 29.690
Authors: Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño Journal: Clin J Am Soc Nephrol Date: 2010-06-10 Impact factor: 8.237
Authors: Gerasimos S Filippatos; Mustafa I Ahmed; James D Gladden; Marjan Mujib; Inmaculada B Aban; Thomas E Love; Paul W Sanders; Bertram Pitt; Stefan D Anker; Ali Ahmed Journal: Eur Heart J Date: 2011-01-03 Impact factor: 29.983
Authors: Sunil V Badve; Fiona Brown; Carmel M Hawley; David W Johnson; John Kanellis; Gopala K Rangan; Vlado Perkovic Journal: Nat Rev Nephrol Date: 2011-02-15 Impact factor: 28.314